I-Mab to Provide Business and Corporate Updates and Report Financial Results for the Six Months Ended June 30, 2021 on August 31, 2021

Rhea-AI Summary

I-Mab (Nasdaq: IMAB) announced its intention to present business updates and report financial results for the six months ending June 30, 2021, on August 31, 2021. The reports will be shared during conference calls held in Mandarin at 7:00 a.m. ET and in English at 8:00 a.m. ET. I-Mab specializes in the development of novel biologics aimed at immuno-oncology and autoimmune diseases, with over 10 drug candidates in its pipeline. The company aims to evolve from a clinical-stage to a fully integrated global biopharmaceutical entity.

SHANGHAI and GAITHERSBURG, Md., Aug. 17, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced it will provide business and corporate updates and report financial results for the six months ended June 30, 2021, before the market opens on Tuesday, August 31, 2021. The Company's management will host conference calls to discuss the results and updates.

On August 31, 2021, a Mandarin session conference call will be held at 7:00 a.m. ET, and an English session conference call will be held at 8:00 a.m. ET. The conference calls can be accessed by the following Zoom links:

Mandarin Session

Meeting URL:	https://zoom.us/j/96267698618?pwd=S3p1NzZqdzdtQnZmS2lEbUpkeGk5Zz09
Meeting ID:	962 6769 8618
Password:	781902

English Session

Meeting URL:	https://zoom.us/j/99563840425?pwd=VTNTbUNFOHJhY1ptZFpkbU93WDBKUT09
Meeting ID:	995 6384 0425
Password:	819127

About I-Mab

I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development, and soon commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to transition from a clinical-stage biotech company toward a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, world-class GMP manufacturing facilities, and commercial capability. I-Mab has offices in Beijing, Shanghai, Hangzhou, Hong Kong, and Maryland, United States. For more information, please visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedIn, Twitter, and WeChat.

For more information, please contact:

I-Mab

Jielun Zhu, Chief Financial Officer
E-mail: jielun.zhu@i-mabbiopharma.com
Office line: +86 21 6057 8000

Gigi Feng, Chief Communications Officer
E-mail: gigi.feng@i-mabbiopharma.com
Office line: +86 21 6057 5709

Investor Inquiries:

The Piacente Group, Inc.
Emilie Wu
E-mail: emilie@thepiacentegroup.com
Office line: + 86 21 6039 8363

View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-provide-business-and-corporate-updates-and-report-financial-results-for-the-six-months-ended-june-30-2021-on-august-31-2021-301356683.html

SOURCE I-Mab

FAQ

When will I-Mab report its financial results?

I-Mab will report its financial results for the six months ended June 30, 2021, on August 31, 2021.

What is the focus of I-Mab's drug development?

I-Mab focuses on developing novel biologics for immuno-oncology and autoimmune diseases.

How can I access the I-Mab conference call?

The conference call can be accessed via Zoom, with a Mandarin session at 7:00 a.m. ET and an English session at 8:00 a.m. ET on August 31, 2021.

What is the stock symbol for I-Mab?

The stock symbol for I-Mab is IMAB, and it is listed on Nasdaq.